Triapine and a more potent dimethyl derivative induce endoplasmic reticulum stress in cancer cells

Robert Trondl1, Lea S Flocke, Christian R Kowol

  • 1Institute of Inorganic Chemistry, University of Vienna, Vienna, Austria (R.T., L.S.F., C.R.K., M.A.J., B.K.K.); Research Platform "Translational Cancer Therapy Research" (R.T., C.R.K., P.H., U.J., M.A.J., W.B., B.K.K.), Institute of Cancer Research (P.H., U.J., W.B.), and Comprehensive Cancer Centre (P.H., U.J., W.B.), Medical University of Vienna, Vienna, Austria; Genomics Core Facility, VetCore, University of Veterinary Medicine, Vienna, Austria (G.E.M., R.S.); Department of Inorganic and Analytical Chemistry, University of Szeged, Szeged, Hungary (E.A.E.); and Hungarian Academy of Science-USZ Bioinorganic Chemistry Research Group, Szeged, Hungary (E.A.E.).

Molecular Pharmacology
|January 1, 2014
PubMed

Insights

Triapine (3-AP) and its derivative 3-AP-Me induce cancer cell apoptosis by activating endoplasmic reticulum (ER) stress pathways. Terminal dimethylation in 3-AP-Me enhances this ER stress-mediated anticancer effect.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cellular Stress Response

Background:

  • Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP) is a ribonucleotide reductase inhibitor with established clinical trial evaluations.
  • The role of endoplasmic reticulum (ER) stress in the anticancer mechanisms of 3-AP and its derivative N(4),N(4)-dimethyl-triapine (3-AP-Me) requires further elucidation.

Purpose of the Study:

  • To investigate the involvement of ER stress in the anticancer activity of 3-AP and 3-AP-Me.
  • To compare the effects of 3-AP and 3-AP-Me on ER stress pathways and downstream apoptotic events in colon cancer cells.

Main Methods:

  • Treatment of colon cancer cells with 3-AP or 3-AP-Me.
  • Assessment of ER stress markers including PERK, IRE1a, ATF6 pathways, eIF2α phosphorylation, ATF4 and ATF6 gene expression, and XBP1 splicing.
  • Analysis of stress-activated kinases (JNK, p38), proapoptotic protein expression (CHOP, Bim), mitochondrial membrane potential, and antiproliferative effects in the presence of cycloheximide.

Main Results:

  • Both 3-AP and 3-AP-Me activated all three major ER stress pathways, leading to eIF2α phosphorylation and upregulation of ATF4 and ATF6.
  • 3-AP-Me induced a significant 16-fold upregulation of spliced XBP1 mRNA and a more pronounced mitochondrial membrane depolarization compared to 3-AP.
  • Activation of JNK and p38 kinases was observed, and JNK inhibition antagonized the cytotoxic effects. Upregulation of CHOP and Bim indicated ER stress-induced apoptosis, which was reduced by inhibiting protein synthesis.

Conclusions:

  • 3-AP and 3-AP-Me induce apoptosis in colon cancer cells primarily through the activation of ER stress.
  • The terminal dimethylation in 3-AP-Me results in a more potent induction of ER stress and subsequent apoptosis compared to 3-AP.
  • ER stress induction is a significant contributor to the anticancer mode of action for both Triapine and its derivative 3-AP-Me.

Related Concept Videos

The Unfolded Protein Response01:37

The Unfolded Protein Response

The ER is the hub of protein synthesis in a cell. It has robust systems to quality control protein folding and also for degradation of terminally misfolded proteins. Under normal conditions, a small proportion of misfolded proteins that cannot be salvaged need to be transported to the cytoplasm by the ER-associated degradation or ERAD pathways. However, if the ERAD cannot handle the misfolded proteins, the cell activates the unfolded protein response or UPR to adjust the protein folding...
5.6K
Regulation of the Unfolded Protein Response01:31

Regulation of the Unfolded Protein Response

Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.2K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Role of ER in the Secretory Pathway01:17

Role of ER in the Secretory Pathway

Eukaryotic cells have a special pathway that enables communication between various intracellular membrane-bound compartments and also with the extracellular environment. This pathway is termed as the secretory pathway.
Components of the secretory pathway
About a third of proteins synthesized in the cell are sorted via the secretory route. They shuffle between different compartments in membrane-bound vesicles until they reach their final destination. The main intracellular compartments involved...
6.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K